Navigation Links
Lombardi Cancer Center's Toretsky awarded prestigious Burroughs Wellcome Fund Award
Date:3/7/2008

Jeffrey A. Toretsky, M.D., a pediatric oncology physician and researcher at Georgetown University's Lombardi Comprehensive Cancer Center has received a prestigious Clinical Scientist Award in Translational Research from the Burroughs Wellcome Fund (BWF). The $750,000 award, one of only 13 given in 2008, is "intended to support established, independent physician-scientists who are dedicated to translational research -- the two-way transfer between laboratory research and patient treatment -- and mentoring physician-scientist trainees."

According to the BWF, "The award provides the freedom and flexibility to explore scientific questions, apply the resulting knowledge at the bedside, and bring insights from the clinical setting back to the laboratory for further study."

Translational Research Awards provide $150,000 per year over five years.

"We hope these awards will lead to better understanding of the mechanisms of disease as well as new methods of diagnosing, treating and preventing disease," said BWF President Enriqueta C. Bond, Ph.D. "BWF particularly is interested in supporting physician-scientists who bring novel ideas and new approaches to translational research."

Toretsky actively pursues research that will lead to new and more specific therapies for Ewing's sarcoma, a solid tumor in bone or soft tissue that primarily occurs in children and young adults. Specifically, the focus of his research is to identify the molecular mechanisms of a gene mutated in Ewing's sarcoma, known as EWS-FLI1, and to develop therapeutic inhibitors against this protein to treat the disease.

"This award will significantly aid us in advancing our work in Ewing's sarcoma and I'm truly honored," said Toretsky. "Specifically, we'll use the award to accelerate our efforts in finding new treatments for this cancer by engaging a unique drug discovery laboratory at Georgetown."

The drug discovery program at Georgetown University Medical Center, led by Milton Brown, Ph.D, is uniquely positioned at the interface of chemistry and medicine to facilitate the translation of basic science towards new medical therapies.

"It's a privilege to work with Milt and a team of chemists and biologists to address a specific cancer problem," said Toretsky. "This kind of interaction is required to truly impact the progress of translational research and drug discovery. Ewing's sarcoma is rare, but our work has the potential to improve treatment not only for patients with this disease but for others who have cancers with similar molecular characteristics."

His sentiments were echoed by Louis M. Weiner, MD, director of the Lombardi Comprehensive Cancer Center, who noted, "The collaboration between Jeff Toretsky and Milt Brown exemplifies the Lombardi's commitment to creating multi-investigator collaborations that focus on translational research. Their work will directly lead to the improved understanding and treatment of Ewing's sarcoma. Support from the Burroughs Wellcome Fund will provide critical resources to enable this important work."

Toretsky divides his time between clinical practice as a pediatric hematologist/oncologist and his research laboratory. In addition to Ewing's sarcoma, his clinical interests include rare pediatric hematology diseases and childhood cancers, in particular osteosarcoma (bone cancer) and synovial sarcoma.

Toretsky received his BS from the University of Wisconsin, Madison in 1984 and his MD in 1988 from the University of Minnesota. He completed his pediatric residency at the Medical College of Virginia in 1991, and his pediatric oncology fellowship at the National Cancer Institute Pediatric Branch in 1994. He came to Lombardi in 2002 from the Departments of Pediatrics and Biochemistry and Molecular Biology at the University of Maryland.


'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
414-312-7085
Georgetown University Medical Center
Source:Eurekalert

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... February 17, 2017 , ... Focused ... innovation in the industry, according to the recent NEJM Catalyst Insights Report on ... of the NEJM Catalyst Insights Council, a qualified group of U.S. executives, clinical ...
(Date:2/18/2017)... ... 2017 , ... A new directory from the Senior Veterans ... connect elderly veterans of America's armed forces to a range of senior care ... on this year's increase in the Veterans Pension with Aid & Attendance for ...
(Date:2/17/2017)... ... 2017 , ... For the first time, International Scholarship and ... floor for the 2017 HIMSS Conference & Exhibition at the Orange ... than 40,000 healthcare industry professionals are expected at the conference, where they will ...
(Date:2/17/2017)... ... February 17, 2017 , ... Access today ... Exhibition in Orlando, Fla., February 19-23. Visitors to the company’s booth (#1778) will ... used electronic patient signatures solution in healthcare . , Since it first ...
(Date:2/17/2017)... ... February 17, 2017 , ... Cancer diagnostics workflow solution provider ... 20 – 22 in San Francisco. As part of the Tri-Conference expo, which ... workflow solution, as well as its new precision medicine platform, “Crosswalk Insight: Oncology™.” ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... the development and commercialization of innovative therapies for ... Vincent J. Angotti has been appointed ... company,s board of directors, effective Monday, March 6, ... experience leading executive and commercial teams at public ...
(Date:2/16/2017)... , Feb. 16, 2017  Prescription pain medications ... department visit are necessary for long-term opioid use to ... Feb. 16 th edition of The New ... "Emergency physicians see more patients in acute pain than ... Parker , MD, FACEP, president of the American College ...
(Date:2/16/2017)... Research and Markets has announced the addition of the ... Function, Application, Cancer Type, Technology - Forecast to 2025" report ... ... grow at a CAGR of around 28.6% over the next decade ... Some of the prominent trends that the market is witnessing include ...
Breaking Medicine Technology: